The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
The results of this meta-analysis by University of Cambridge-led team could have implications for LDL-C-lowering therapies.
Researchers saw both short- and long-term changes in metabolite profiles in blood plasma from individuals who'd undergone Roux-en-Y gastric bypass surgery.
Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.
The core technology uses proximity-ligated amplification and the firm will build it into tests for type I diabetes as well as highly multiplexed assays.
In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.
University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.
In Nature this week: rare variants contribute little risk to type 2 diabetes, atlas of gene expression in developing primate brain, and more.
Genomic data for more than 125,000 individuals uncovered type 2 diabetes risk variants, many appearing at loci identified through common variant association studies.
The researchers plan to use the award to improve upon existing approaches to analysis of longitudinal proteomics data in the context of type I diabetes.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
One gene regulates hundreds of others to influence facial development, according to New Scientist.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.